LMR Partners LLP Buys New Stake in Stevanato Group S.p.A. (NYSE:STVN)

LMR Partners LLP bought a new stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,956 shares of the company's stock, valued at approximately $413,000.

Several other hedge funds and other institutional investors have also bought and sold shares of STVN. Granahan Investment Management LLC increased its position in shares of Stevanato Group by 95.2% during the 4th quarter. Granahan Investment Management LLC now owns 226,401 shares of the company's stock valued at $4,933,000 after purchasing an additional 110,418 shares during the last quarter. Frontier Capital Management Co. LLC increased its holdings in Stevanato Group by 1,012.0% in the 4th quarter. Frontier Capital Management Co. LLC now owns 1,003,235 shares of the company's stock worth $21,860,000 after acquiring an additional 913,019 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Stevanato Group in the 4th quarter worth approximately $281,000. Balyasny Asset Management L.P. increased its holdings in Stevanato Group by 14.2% in the 4th quarter. Balyasny Asset Management L.P. now owns 186,447 shares of the company's stock worth $4,063,000 after acquiring an additional 23,230 shares in the last quarter. Finally, Bamco Inc. NY increased its holdings in Stevanato Group by 7.9% in the 4th quarter. Bamco Inc. NY now owns 1,818,181 shares of the company's stock worth $39,618,000 after acquiring an additional 133,000 shares in the last quarter.

Stevanato Group Price Performance

STVN traded down €0.43 ($0.48) during trading on Tuesday, reaching €24.35 ($27.36). 85,798 shares of the company traded hands, compared to its average volume of 345,298. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. Stevanato Group S.p.A. has a 12-month low of €16.56 ($18.61) and a 12-month high of €25.75 ($28.93). The firm has a fifty day simple moving average of €21.50 and a 200 day simple moving average of €21.23. The company has a market cap of $7.37 billion, a P/E ratio of 51.81, a PEG ratio of 7.18 and a beta of 0.51.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. On average, equities analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be issued a dividend of $0.0613 per share. This is a positive change from Stevanato Group's previous annual dividend of $0.05. This represents a yield of 0.3%. The ex-dividend date is Thursday, June 5th. Stevanato Group's dividend payout ratio (DPR) is 11.76%.

Wall Street Analyst Weigh In

STVN has been the subject of several analyst reports. Stephens raised shares of Stevanato Group to a "strong-buy" rating in a report on Monday, April 21st. William Blair reissued an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. Finally, UBS Group reduced their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Stevanato Group has an average rating of "Moderate Buy" and a consensus target price of €25.70 ($28.88).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.